In This Article:
The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027, the agency said in a statement. The selected drug list for the second cycle of negotiations is: Novo Nordisk’s (NVO) Ozempic, Rybelsus, and Wegovy, GSK‘s (GSK) Trelegy Ellipta, Pfizer’s (PFE) Xtandi, Bristol Myers’ (BMY) Pomalyst, Pfizer’s (PFE) Ibrance, Boehringer Ingleheim’s Ofev, AbbVie (ABBV) and Ironwood’s (IRWD) Linzess, AstraZeneca’s (AZN) Calquence, Teva‘s (TEVA) Austedo, GSK and Theravance’s (TBPH) Breo Ellipta, Boehringer’s Tradjenta, Salix’s (BHC) Xifaxan, AbbVie’s Vraylar, Merck’s (MRK) Janumet, and Amgen’s (AMGN) Otezla. Companies with a selected drug will have until February 28 to decide if they will participate in negotiations.
Stay Ahead of the Market:
-
Discover outperforming stocks and invest smarter with Top Smart Score Stocks
-
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVO: